The Decent Value screen is built on a principle that value investors have followed for decades: do not buy a stock for the low price alone; look for a company that is cheap relative to its fundamentals and still backed by real financial strength. The screen applies this idea by requiring a strong valuation score while filtering for solid profitability, healthy balance sheets, and acceptable growth. That combination is designed to avoid the classic value trap, where a depressed share price merely reflects a deteriorating business. One company that currently passes these tests is EXELIXIS INC (NASDAQ:EXEL), an oncology-focused drug developer whose fundamentals stand out across multiple dimensions.
A valuation that stands out against the sector
Exelixis carries a ChartMill valuation rating of 7 out of 10, and the underlying price ratios explain why the screen considers it attractive. The trailing price-to-earnings ratio of 17.01 is well below the biotechnology industry average of roughly 42.6, which means the market is assigning a notably lower multiple to this company than to most of its peers. The forward P/E of 14.41 reinforces that picture, as does a comparison with the S&P 500, where the average forward multiple sits around 21.7.
The same pattern appears on other valuation measures:
- EV/EBITDA: cheaper than roughly 96% of industry peers
- Price/free cash flow: cheaper than roughly 98% of industry peers
- PEG ratio (NY): considered fairly valued when growth is taken into account
For value investors, this suggests the market has not yet fully recognized the company's earnings power. A complete breakdown of these ratios and their context is available in the fundamental analysis report.
Profitability: high-quality earnings behind the low multiple
A low valuation is only meaningful if the underlying business is fundamentally sound, and that is where Exelixis makes its case. The company earns a profitability rating of 9 out of 10, supported by returns that rank at or near the top of its industry:
- Return on assets: 34.50%, better than 98% of peers
- Return on equity: 46.68%, better than 97% of peers
- Return on invested capital: 37.13%, better than 99% of peers
- Profit margin: 35.33%, with an operating margin of 40.72%
- Gross margin: 96.48%
These numbers indicate a business that converts revenue into profit with unusual efficiency. That matters for the Decent Value strategy because it reduces the chance that the attractive price is simply a reflection of weak operations.
Financial health: a balance sheet with no debt
The health rating is another 9 out of 10, and the details are worth noting for a company in the capital-intensive biotech space. Exelixis has no outstanding debt, so its debt-to-equity and debt-to-free-cash-flow ratios are both zero. Its Altman-Z score of 15.02 points to minimal near-term bankruptcy risk, while the current ratio of 3.46 and quick ratio of 3.38 indicate that short-term obligations are comfortably covered.
For value investors, balance sheet strength is a critical part of the margin of safety. A cheap stock can quickly become a permanent capital loss if the company is forced to raise dilutive capital or struggle with heavy debt repayments. Exelixis sidesteps that risk entirely.
Growth: still expanding, though at a slower pace
The growth rating of 6 out of 10 is the more moderate part of the profile, but it still supports the overall thesis. Over the past year, earnings per share grew by 52.88%, and revenue grew by 9.23%. On a multiyear basis, EPS has risen by 51.25% per year on average, with revenue growing at an average annual rate of 18.63%.
Looking ahead, analysts expect EPS growth of about 8.35% per year and revenue growth of around 5.49% per year over the next few years. The screen's assessment notes that this represents a deceleration compared with recent history, which keeps the growth score from being higher. Still, the combination of a forward P/E of 14.41 and expected earnings growth of 18.40% in the coming years leaves room for the valuation to become more attractive as the market prices in future results.
Why these criteria matter for value investors
The Decent Value methodology starts from the observation that a low price-to-earnings ratio on its own is not a sufficient reason to buy. A value trap appears when a stock looks cheap but the underlying business is deteriorating; cyclical weakness, expiring patents, or structural shifts can all turn a bargain into a permanent loss of capital. By insisting on strong profitability, a clean balance sheet, and positive growth alongside a reasonable valuation, the screen attempts to make sure the margin of safety is built on real fundamentals.
Exelixis is not without risks. The expected deceleration in growth, the lack of a dividend, and the inherent uncertainty of drug development and commercialization in oncology are all factors that value investors should weigh. But for a company trading below 15 times forward earnings with top-tier profitability and no debt, those risks are reflected in a price that still leaves room for upside if execution continues.
Other screens confirm the quality angle
Separate from the Decent Value methodology, EXEL also shows up on screens built around business quality. The High ROIC screen confirms that the company allocates capital efficiently, and the High Free Cash Flow screen shows it generates enough cash to remain flexible. These are exactly the kinds of quality signals that separate a genuine value stock from a value trap.
The bottom line
Exelixis offers a combination that is relatively rare in the biotechnology sector: an attractive valuation, best-in-class profitability, a balance sheet with no debt, and a pipeline that still supports future growth. For value investors, that is precisely the profile the Decent Value screen is designed to find. Investors who want to explore other stocks that meet this same combination of valuation and quality can review the full list of stocks matching the Decent Value methodology.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals
The Decent Value screen is built on a principle that value investors have followed for decades: do not buy a stock for the low price alone; look for a company that is cheap relative to its fundamentals and still backed by real financial strength. The screen applies this idea by requiring a strong valuation score while filtering for solid profitability, healthy balance sheets, and acceptable growth. That combination is designed to avoid the classic value trap, where a depressed share price merely reflects a deteriorating business. One company that currently passes these tests is EXELIXIS INC (NASDAQ:EXEL), an oncology-focused drug developer whose fundamentals stand out across multiple dimensions.
A valuation that stands out against the sector
Exelixis carries a ChartMill valuation rating of 7 out of 10, and the underlying price ratios explain why the screen considers it attractive. The trailing price-to-earnings ratio of 17.01 is well below the biotechnology industry average of roughly 42.6, which means the market is assigning a notably lower multiple to this company than to most of its peers. The forward P/E of 14.41 reinforces that picture, as does a comparison with the S&P 500, where the average forward multiple sits around 21.7.
The same pattern appears on other valuation measures:
For value investors, this suggests the market has not yet fully recognized the company's earnings power. A complete breakdown of these ratios and their context is available in the fundamental analysis report.
Profitability: high-quality earnings behind the low multiple
A low valuation is only meaningful if the underlying business is fundamentally sound, and that is where Exelixis makes its case. The company earns a profitability rating of 9 out of 10, supported by returns that rank at or near the top of its industry:
These numbers indicate a business that converts revenue into profit with unusual efficiency. That matters for the Decent Value strategy because it reduces the chance that the attractive price is simply a reflection of weak operations.
Financial health: a balance sheet with no debt
The health rating is another 9 out of 10, and the details are worth noting for a company in the capital-intensive biotech space. Exelixis has no outstanding debt, so its debt-to-equity and debt-to-free-cash-flow ratios are both zero. Its Altman-Z score of 15.02 points to minimal near-term bankruptcy risk, while the current ratio of 3.46 and quick ratio of 3.38 indicate that short-term obligations are comfortably covered.
For value investors, balance sheet strength is a critical part of the margin of safety. A cheap stock can quickly become a permanent capital loss if the company is forced to raise dilutive capital or struggle with heavy debt repayments. Exelixis sidesteps that risk entirely.
Growth: still expanding, though at a slower pace
The growth rating of 6 out of 10 is the more moderate part of the profile, but it still supports the overall thesis. Over the past year, earnings per share grew by 52.88%, and revenue grew by 9.23%. On a multiyear basis, EPS has risen by 51.25% per year on average, with revenue growing at an average annual rate of 18.63%.
Looking ahead, analysts expect EPS growth of about 8.35% per year and revenue growth of around 5.49% per year over the next few years. The screen's assessment notes that this represents a deceleration compared with recent history, which keeps the growth score from being higher. Still, the combination of a forward P/E of 14.41 and expected earnings growth of 18.40% in the coming years leaves room for the valuation to become more attractive as the market prices in future results.
Why these criteria matter for value investors
The Decent Value methodology starts from the observation that a low price-to-earnings ratio on its own is not a sufficient reason to buy. A value trap appears when a stock looks cheap but the underlying business is deteriorating; cyclical weakness, expiring patents, or structural shifts can all turn a bargain into a permanent loss of capital. By insisting on strong profitability, a clean balance sheet, and positive growth alongside a reasonable valuation, the screen attempts to make sure the margin of safety is built on real fundamentals.
Exelixis is not without risks. The expected deceleration in growth, the lack of a dividend, and the inherent uncertainty of drug development and commercialization in oncology are all factors that value investors should weigh. But for a company trading below 15 times forward earnings with top-tier profitability and no debt, those risks are reflected in a price that still leaves room for upside if execution continues.
Other screens confirm the quality angle
Separate from the Decent Value methodology, EXEL also shows up on screens built around business quality. The High ROIC screen confirms that the company allocates capital efficiently, and the High Free Cash Flow screen shows it generates enough cash to remain flexible. These are exactly the kinds of quality signals that separate a genuine value stock from a value trap.
The bottom line
Exelixis offers a combination that is relatively rare in the biotechnology sector: an attractive valuation, best-in-class profitability, a balance sheet with no debt, and a pipeline that still supports future growth. For value investors, that is precisely the profile the Decent Value screen is designed to find. Investors who want to explore other stocks that meet this same combination of valuation and quality can review the full list of stocks matching the Decent Value methodology.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »